The present application falls within the field of medicinal chemistry, relates to the crystal of a compound as a c-Met kinase inhibitor, and specifically relates to the crystal of N-(4-((7-((1-(cyclopentylamino)cyclopropyl)methoxy)-6-methoxyquinolin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and a preparation method therefor, a crystalline composition thereof, and a pharmaceutical composition thereof, as well as the use of the crystal for treating diseases associated with the inhibition of growth factor receptor protein tyrosine kinase activity. The crystal of the present application has excellent properties in at least one of the following aspects: pharmacokinetics, bioavailability, hygroscopicity, stability, solubility, purity, ease of preparation, etc.
